Sandeep Chidambar Kulkarni - 03 Feb 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
CEO, Director
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
03 Feb 2025
Net transactions value
$0
Form type
4
Filing time
04 Feb 2025, 16:19:06 UTC
Previous filing
11 Dec 2024
Next filing
22 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Employee Stock Option (Right to Buy) Award $0 +226,000 $0.000000 226,000 03 Feb 2025 Common Stock 226,000 $15.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as to 25% of the shares on February 3, 2026, with the remainder vesting in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.